Immunic Inc IMUX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-04-17 |
| Shares Out. | 13,620,000 |
| Website | imux.com ↗ |
| Phone | 13026587581 |
| Employees | 95 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$34.1M |
| Free Cash Flow | -$88.0M |
| Total Assets | $159.2M |
| Total Liabilities | $31.6M |
| Equity | $127.6M |
About Immunic Inc
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Immunic Inc is a publicly traded company under the ticker symbol IMUX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-09-01)